Research progress in immune checkpoint inhibitors-induced immune-mediated liver injury
Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China; Department of Pharmacy, Shandong First Medical University, Shandong Province, Taian 271016, China
Abstract：Immune checkpoint inhibitors (ICIs)-associated immune-mediated hepatitis (IMH) is a special type of drug-induced liver injury. The risk factors of IMH include combination of different types of ICIs, comorbidities, fever, etc. Most patients with IMH are asymptomatic, but laboratory tests show mainly abnormal levels of serum transaminase. It is crucial for patients with IMH to stop or delay the use of ICIs and receive immunosuppressive therapy. The immunosuppressive therapy for IMH usually includes glucocorticoids, and the immunosuppressive agents such as tacrolimus, mycophenolate mofetil, etc. can also be added.
张文，王旭升，刘云霞，卢翠翠. 免疫检查点抑制剂致免疫介导性肝损伤研究进展[J]. 药物不良反应杂志, 2021, 23(1): 30-34.
Zhang Wen, Wang Xusheng, Liu Yunxia, Lu Cuicui. Research progress in immune checkpoint inhibitors-induced immune-mediated liver injury. Adverse Drug Reactions Journal, 2021, 23(1): 30-34.
